Enhanced Antitumor Efficacy and Reduced Systemic Toxicity of Sulfatide-Containing Nanoliposomal Doxorubicin in a Xenograft Model of Colorectal Cancer

• Jia Lin,

  Affiliation School of Medicine, Faculty of Health, Deakin University, Waurn Ponds, Victoria, Australia

  ⨯
• Yan Yu,

  Affiliation School of Medicine, Faculty of Health, Deakin University, Waurn Ponds, Victoria, Australia

  ⨯
• Sarah Shigdar,

  Affiliation School of Medicine, Faculty of Health, Deakin University, Waurn Ponds, Victoria, Australia

  ⨯
• Ding Zhi Fang,

  Affiliation Department of Biochemistry and Molecular Biology, West China School of Preclinical and Forensic Medicine, Sichuan University, Chengdu, People’s Republic of China

  ⨯
• Jun Rong Du,

  Affiliation Department of Pharmacology and Biopharmaceutics, West China School of Pharmacy, Sichuan University, Chengdu, People’s Republic of China

  ⨯
• Ming Q. Wei,

  Affiliation School of Medical Science and Griffith Health Institute, Griffith University, Gold Coast Campus, Southport, Australia

  ⨯
• Andrew Danks,

  Affiliation Department of Neurosurgery, Monash Medical Centre, Monash University, Clayton, Victoria, Australia

  ⨯
• Ke Liu,

  Affiliation Faculty of Life Sciences, Sichuan University, Chengdu, People’s Republic of China

  ⨯
• Wei Duan

  * E-mail: wduan@deakin.edu.au

  Affiliation School of Medicine, Faculty of Health, Deakin University, Waurn Ponds, Victoria, Australia

  ⨯